Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

VK2809 · MB-07811

Small molecule · developed by Viking Therapeutics

Phase 2 Most advanced trial (none active)
VKTX Developer
1 Registered trials

What is VK2809?

VK2809 is an investigational small-molecule drug studied in NASH - Nonalcoholic Steatohepatitis.

At a glance

Also known as
MB-07811
Drug type
Small molecule
Therapy area
Gastroenterology
Developer
Viking Therapeutics, Inc. (VKTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
3Z11398FNQ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04173065 Phase 2 NASH - Nonalcoholic Steatohepatitis Completed VKTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

NASH - Nonalcoholic Steatohepatitis

More from Viking Therapeutics

VK0214 Investigational VK2735 Investigational VK5211 Investigational

Follow VKTX, the company behind VK2809

See VKTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VKTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.